Table 1.
Participant characteristics of each trial
| Trial and regimen | No randomised | Mean (SD) age (years) | Men (%) | Smokers (%) | Hypertensive (%) | Cholesterol (mmol/l) | Time to angiography (days) | Proportion not receiving angiography (%) |
|---|---|---|---|---|---|---|---|---|
| Gavaghan42: | ||||||||
| Aspirin 324 mg | 127 | 56 (7) | 87 | 65 | 45 | 7.1 | 363* (median) | 8* |
| Placebo | 110 | 56 (6) | 84 | 67 | 39 | 7.0 | 363* (median) | 8* |
| Goldman41: | ||||||||
| Aspirin 325 mg | 104 | 59 (8) | 100 | NA | 47 | 5.9 | 367* (median) | 35* |
| Placebo | 107 | 58 (8) | 100 | NA | 53 | 5.7 | 367* (medain) | 35* |
| Lorenz40: | ||||||||
| Aspirin 100 mg | 29† | 55 (10) | 83 | NA | NA | 6.9 | 131 (mean) | 24 |
| Placebo | 31† | 55 (6) | 90 | NA | NA | 7.2 | 129 (mean) | 23 |
| Sanz43: | ||||||||
| Aspirin 150 mg | 373 | 57 (8) | 90 | 65 | 40 | 6.0 | 10 (mean) | 17* |
| Placebo | 371 | 56 (8) | 89 | 68 | 38 | 6.0 | 11 (mean) | 17* |
| Hockings44: | ||||||||
| Aspirin 100 mg | 50 | 60 (9) | 94 | N/A | 50 | NA | 180* (NA) | 27* |
| Placebo | 52 | 60 (9) | 92 | N/A | 31 | NA | 180* (NA) | 27* |
NA=not available.
*
Value reported for entire study cohort.
†
Number of patients reported at end of study.